Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2000
11/21/2000US6149925 Applying cosmetic or pharmaceutical composition comprising effective amounts of a glycine compound, a glutamine compound, and a sulfhydryl-containing organic acid, and carrier to skin
11/21/2000US6149924 For topical application
11/21/2000US6149923 Antirheumatic agent
11/21/2000US6149922 Vaccine adjuvant and vaccine
11/21/2000US6149915 Administering a herb salviae miltiorrhizae radix
11/21/2000US6149912 Method to enhance innate immunity defense mechanisms by treatment with plant-derived alkaloids
11/21/2000US6149908 Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating Helicobacter pylori infection
11/21/2000US6149904 Administering an engineered non-tumorigenic cells that express a second heterologous nucleic acid that encodes a pro-drug activating molecule that converts a nontoxic substrate to a toxic metabolite
11/21/2000US6149902 Manipulation of non-terminally differentiated cells using the notch pathway
11/21/2000US6149896 Cosmetic and cosmeceutical compositions
11/21/2000US6149892 Metered dose inhaler for beclomethasone dipropionate
11/21/2000US6149671 Laser/sensitizer assisted immunotherapy
11/21/2000US6149652 Spine distraction implant and method
11/21/2000US6149641 Local delivery of estrogen for angiogenesis
11/21/2000CA2187309C Tropane-2-aldoxime derivatives as neurotransmitter reuptake inhibitors
11/21/2000CA2117528C Facilitated oxygen delivery in conjunction with hemodilution
11/21/2000CA2105502C Insulin secretion stimulating composition for the treatment of non-insulin-dependent diabetes
11/21/2000CA2093433C Sertindole prodrugs
11/21/2000CA2083639C Substituted phenyl phenol leukotriene antagonists
11/21/2000CA2081482C Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
11/21/2000CA2054189C Stable ascorbic acid compositions
11/21/2000CA2040854C Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
11/21/2000CA2031150C Sustained-release drug dosage units
11/21/2000CA2027842C Treatment for multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
11/21/2000CA2024631C Double-coated granules of disodium pamidronate
11/21/2000CA2019812C Novel 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones and their use in the prevention or treatment of aids
11/21/2000CA2016513C Process for 3-exomethylenecepham sulfoxide esters
11/21/2000CA2010085C Pentamidine solutions
11/18/2000CA2684454A1 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
11/16/2000WO2000068413A1 Halo- or hydroxy-substituted nocathiacin antibiotics
11/16/2000WO2000068399A2 Vector-mediated delivery of integrating transposon sequences
11/16/2000WO2000068384A2 NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068247A2 Serine proteases
11/16/2000WO2000068246A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000WO2000068245A1 14β-H-STEROLS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEIOSIS REGULATING MEDICAMENTS
11/16/2000WO2000068241A1 Processes for the synthesis of oligomers using phusphoramidite compositions
11/16/2000WO2000068231A1 Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
11/16/2000WO2000068229A2 (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
11/16/2000WO2000068226A1 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds
11/16/2000WO2000068225A1 Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa
11/16/2000WO2000068224A1 Substituted benzolactam compounds
11/16/2000WO2000068223A1 Ureas and their use as cell adhesion modulators
11/16/2000WO2000068216A1 Fused 1,2,6-thiadiazine -n,n and n,x-disubstituted dioxide derivatives and corresponding production method
11/16/2000WO2000068215A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000WO2000068213A1 Substituted bicyclic compounds
11/16/2000WO2000068209A2 1,5-benzodiazepine derivatives as cck-a receptor agonists
11/16/2000WO2000068208A1 Pyrimidinones derivatives for the treatment of atherosclerosis
11/16/2000WO2000068206A1 Heterocyclically substituted benzimidazoles, the production and application thereof
11/16/2000WO2000068203A1 Cyclic compounds and uses thereof
11/16/2000WO2000068202A1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
11/16/2000WO2000068201A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068200A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068199A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000068195A2 Substituted pyrrolidines as cell adhesion inhibitors
11/16/2000WO2000068194A1 Iminocyclitol inhibitors of hexoaminidase and glycosidase
11/16/2000WO2000068191A1 Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity
11/16/2000WO2000068188A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000068184A1 Aromatic amides
11/16/2000WO2000068183A2 High purity (1r,2s,4r)-(-)-2-[(2'-{n,n-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them
11/16/2000WO2000068181A2 Process for preparing (1r,2s,4r) -(-)-2-[(2'- {n,n-dimethylamino} -ethoxy)] -2-[phenyl] -1,7,7-tri- [methyl] -bicyclo [2.2.1] heptane and pharmaceutically acceptable acid addition salts thereof
11/16/2000WO2000067917A1 Permeabilizing biofilms
11/16/2000WO2000067847A2 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
11/16/2000WO2000067801A2 Prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/16/2000WO2000067800A2 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates
11/16/2000WO2000067799A1 Compositions for treatment of disorders of the oesophagus
11/16/2000WO2000067798A2 Enhanced delivery of nucleic acid-based drugs
11/16/2000WO2000067797A1 Composition providing a sustained release of l-histidine and methods of manufacture thereof
11/16/2000WO2000067795A1 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
11/16/2000WO2000067776A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000WO2000067773A2 Combinations of immunosupressive agents for the treatment or prevention of graft rejections
11/16/2000WO2000067772A1 Galenic formulations of argatroban for subcutaneous administration
11/16/2000WO2000067769A1 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
11/16/2000WO2000067766A1 Restorative and regenerative preparation, method for producing the same and therapeutical use according to l.v. dubinina
11/16/2000WO2000067762A2 Selenium-containing pro-drugs for cancer therapy
11/16/2000WO2000067760A1 Liposome preparation of fat-soluble antitumor drug
11/16/2000WO2000067759A1 Novel, specific inhibitors of acute and chronic inflammation
11/16/2000WO2000067758A1 Remedies for glomerulosclerosis
11/16/2000WO2000067757A1 Treatment of bone cancer
11/16/2000WO2000067756A1 Methods for controlling intraocular pressure
11/16/2000WO2000067755A1 Cyclic amidines useful as nmda nr2b antagonists
11/16/2000WO2000067754A1 Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
11/16/2000WO2000067753A1 Parenteral formulation of 5-(2-chloroethyl)-4-methylthiazole edisylate(clomethiazole edisylate)
11/16/2000WO2000067752A1 Use of succinic acid derivatives to obtain a medicine for treating inflammation
11/16/2000WO2000067751A1 Aryl amidines, compositions containing such compounds and methods of use
11/16/2000WO2000067749A1 Food product
11/16/2000WO2000067748A1 Remedies for renal failure
11/16/2000WO2000067747A1 Docusate hard gelatin capsules
11/16/2000WO2000067746A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067745A1 Cardioprotective composition and uses thereof
11/16/2000WO2000067744A1 Neuroprotective composition and uses thereof
11/16/2000WO2000067743A1 Radical scavenger
11/16/2000WO2000067742A2 Use of gaba analogues for the modulation of substance p
11/16/2000WO2000067741A2 (s,r) formoterol methods and compositions
11/16/2000WO2000067740A2 Aminoguanidine for treating glaucomatous optic neuropathy
11/16/2000WO2000067739A2 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects
11/16/2000WO2000067738A2 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
11/16/2000WO2000067737A2 USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION
11/16/2000WO2000067736A2 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone
1 ... 6207 6208 6209 6210 6211 6212 6213 6214 6215 6216 6217 6218 6219 6220 6221 6222 6223 6224 6225 6226 6227 ... 7860